Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Small-Molecule Inhibition of Human Immunodeficiency Virus Type 1 Replication by Specific Targeting of the Final Step of Virion Maturation

23 Dec 2003

Abstract excerpt

Despite the effectiveness of currently available human immunodeficiency virus type 1 (HIV-1) therapies, a continuing need exists for new drugs to treat HIV-1 infection. We investigated the mechanism by which 3-O-[3',3'-dimethylsuccinyl]-betulinic acid (DSB) inhibits HIV-1 replication. DSB functions at a late stage of the virus life cycle but does not inhibit the HIV-1 protease in vitro or interfere with virus...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Herpesvirus Infections and Treatments
Share to HIV/AIDS drug development and treatment
Share to HIV Research and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 14694123
DOI: 10.1128/jvi.78.2.922-929.2004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Small-Molecule Inhibition of Human Immunodeficiency Virus Type 1 Replication by Specific Targeting of the Final Step of Virion MaturationPMID 14694123Read ↗

Human Immunodeficiency Virus Type 1 Resistance to the Small Molecule Maturation Inhibitor 3- O -(3′,3′-Dimethylsuccinyl)-Betulinic Acid Is Conferred by a Variety of Single Amino Acid Substitutions at the CA-SP1 Cleavage Site in GagSemantic proximity Read ↗

The sequence of the CA-SP1 junction accounts for the differential sensitivity of HIV-1 and SIV to the small molecule maturation inhibitor 3-O-{3',3'-dimethylsuccinyl}-betulinic acidSemantic proximity Read ↗

New Small-Molecule Inhibitor Class Targeting Human Immunodeficiency Virus Type 1 Virion MaturationSemantic proximity Read ↗

PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing.Semantic proximity Read ↗

The discovery of a class of novel HIV-1 maturation inhibitors and their potential in the therapy of HIVSemantic proximity Read ↗

Pharmacological intervention of HIV-1 maturationSemantic proximity Read ↗

In Vitro Resistance to the Human Immunodeficiency Virus Type 1 Maturation Inhibitor PA-457 (Bevirimat)Semantic proximity Read ↗

Bifunctional Anti-Human Immunodeficiency Virus Type 1 Small Molecules with Two Novel Mechanisms of ActionSemantic proximity Read ↗

A Single Polymorphism in HIV-1 Subtype C SP1 Is Sufficient To Confer Natural Resistance to the Maturation Inhibitor BevirimatSemantic proximity Read ↗

Inhibition of HIV replication by capsid mutant C6b.Semantic proximity Read ↗

HIV Capsid is a Tractable Target for Small Molecule Therapeutic InterventionSemantic proximity Read ↗

Impact of human immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor bevirimat (PA-457).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.